Final Agenda

Prostate and Urologic Cancers Collaborative Group Virtual Meeting

Tuesday, June 30, 2020

11:00 a.m. – 6:00 p.m. EDT


O. John Semmes, Ph.D., Eastern Virginia Medical School


Martin Sanda, M.D., Emory University

NCI Program Directors:

Jacob Kagan, Ph.D., M.Sc., and Richard Mazurchuk, Ph.D., National Cancer Institute

11:00 a.m. – 11:20 a.m. EDT

GU01: Welcome and Introduction: Objective, Charge and Progress

  • O. John Semmes, Ph.D., Eastern Virginia Medical School
  • Jacob Kagan, Ph.D., M.Sc., National Cancer Institute
11:20 a.m. – 11:40 a.m. EDT GU02: Guest Speaker: Personalized Strategies to Prostate Cancer Diagnosis
Michael Ahdoot, M.D., National Cancer Institute

11:40 a.m. – 11:50 a.m. EDT


11:50 a.m. – 12:30 p.m. EDT GU Group Collaborative Studies: Updates, Lessons Learned, and What Changes Should be Made
11:50 a.m. – 12:05 p.m. EDT GU03: EDRN Prostate MRI Biomarker Study and Reference Set
John T. Wei, M.D., University of Michigan

12:05 p.m. – 12:10 p.m. EDT


12:10 p.m. – 12:25 p.m. EDT

GU04: Current Status and the Expanded Prostate Cancer Tissue Upgrading Study (URS)

  • Paul Boutros, D., M.B.A., The University of California, Los Angeles
  • Robin Leach, Ph.D., The University of Texas Health Science Center, San Antonio

12:25 p.m. – 12:30 p.m. EDT


12:30 p.m. – 1:00 p.m. EDT

Lunch Break

1:00 p.m. – 3:35 p.m. EDT

GU Teams’ Presentations

  1. What is/are the intended use and/or clinical utility of your marker/s or assay/s?
  2. The state of your marker/s. In which phase is your marker? Did you move your marker/s form development to verification, etc.?
  3. What was accomplished in this cycle of EDRN?
  4. What is the progress and the current state of your trans-network collaborative projects (collaborative projects funded through set-aside funds)?
  5. How does the Network structure benefit your biomarkers development and validation study (how is it better than R01 mechanism?).

Each investigator should submit 1-2 bullet points as potential areas that should be included in the EDRN GU renewal discussions.

1:00 p.m. – 1:15 p.m. EDT GU05: Arul Chinnaiyan, M.D., University of Michigan

1:15 p.m. – 1:20 p.m. EDT


1:20 p.m. – 1:35 p.m. EDT

GU06: Identification of Aggressive Prostate Cancers: In depth Proteomics of Tissues and Urines

  • Thomas Kislinger, Ph.D., Princess Margaret Cancer Centre, University Health Network, University of Toronto
  • Julius Nyalwidhe, Ph.D., Eastern Virginia Medical School

1:35 p.m. – 1:40 p.m. EDT


1:40 p.m. – 1:55 p.m. EDT

GU07: Early detection targeting aggressive prostate cancer
Martin Sanda, M.D., Emory University

1:55 p.m. – 2:00 p.m. EDT


2:00 p.m. – 2:15 p.m. EDT


2:15 p.m. – 2:30 p.m. EDT GU08: Development of an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for Agressive Prostate Cancer
Daniel Chan, Ph.D. and Lori Sokoll, Ph.D., Johns Hopkins University

2:30 p.m. – 2:35 p.m. EDT


2:35 p.m. – 2:50 p.m. EDT GU09: Application of Advanced Proteomic Capabilities to Identify a Tissue-based Classifier Predicting Distant Metastasis or Biochemical Recurrence
Tao Liu, Ph.D., and Karin Rodland, Ph.D., Pacific Northwest National Laboratory

2:50 p.m. – 2:55 p.m. EDT


2:55 p.m. – 3:10 p.m. EDT
GU10: Status, Progress and Future Directions of the USU/CPDR
Gyorgy Petrovics, Ph.D., and Albert Dobi, Ph.D., Center for Prostate Disease Research, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center

3:10 p.m. – 3:15 p.m. EDT


3:15 p.m. – 3:30 p.m. EDT GU11: Discovery and validation of urinary glycoproteins associated with aggressive prostate cancer
Hui Zhang, Ph.D., Johns Hopkins University School of Medicine

3:30 p.m. – 3:35 p.m. EDT


3:35 p.m. – 3:55 p.m. EDT Resources and New Collaborations
3:35 p.m. – 3:50 p.m. EDT GU12: Canary Prostate Cancer Active Surveillance Study (PASS)
Daniel W. Lin, M.D., University of Washington

3:50 p.m. – 3:55 p.m. EDT


3:55 p.m. – 4:10 p.m. EDT


4:10 p.m. – 6:00 p.m. EDT

GU Group Discussion Towards the Renewal of EDRN


  • Martin Sanda M.D., Emory University
  • O. John Semmes, Ph.D., Eastern Virginia Medical School
4:10 p.m. – 4:25 p.m. EDT GU13: The Advocate Perspective
Merel Grey Nissenberg, Esq., NASPCC/Mountain Foundation for Lung Cancer

4:25 p.m. – 4:30 p.m. EDT


4:30 p.m. - 6:00 p.m. EDT


SWOT (Strengths, Weaknesses, Opportunities, and Threats) Analysis

  • Discuss the strengths of EDRN and suggestions how to further strengthen the Network
  • Identify weaknesses and discuss the solutions (Mitigation)
  • Discuss opportunities and highlight prioritized opportunities
  • Discuss threats (competing interests/research) and mitigations

Discussion: What are the next steps?

Are there new concepts and technologies that should be adapted? What will change the biomarker development and validation landscape (e.g., pan-cancer screening tests, advanced imaging and visualization tools, application of Artificial Intelligence (AI) tools)?

  • Discuss pros and cons of Pan-Cancer Detection Approach: Is EDRN ready to adopt such an approach?

How can we improve and streamline the “Development to Validation” pipeline?

Strength and weaknesses of the EDRN collaborative projects (set aside funds and Network Validation studies). How can we improve the process?

What are we missing? What type of markers, assays or cohorts should we focus our research efforts on for strategically expediting future advances?

6:00 p.m. EDT


Version 5.1.0